Share this article on:

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

Hicks, Charlesa; King, Martin Sb; Gulick, Roy Mc; White Jr, A Clintond; Eron Jr, Joseph Je; Kessler, Harold Af; Benson, Constanceg; King, Kathryn Rb; Murphy, Robert Lh; Brun, Scott Cb

Clinical Science: Concise Communications

Objective: Combination antiretroviral therapy with lopinavir/ritonavir (LPV/r) has been highly effective in clinical trials. Results of long-term therapy with LPV/r-based regimens have not been previously reported. This study describes the 4-year (204-week) safety and antiretroviral activity of LPV/r-based treatment in antiretroviral-naive individuals.

Design: Long-term, open-label follow-up of a phase II, prospective, randomized, multicenter trial.

Methods: A group of 100 antiretroviral-naive HIV-infected patients were randomized to one of three blinded doses of LPV/r [200/100 mg (n = 16), 400/100 mg (n = 51), or 400/200 mg (n = 33)] with stavudine 40 mg and lamivudine 150 mg every 12 hours. After 48 weeks, LPV/r was dosed open-label at 400/100 mg every 12 hours with stavudine and lamivudine.

Results: Mean baseline plasma HIV-1 RNA and CD4 cell count were 4.9 log10 copies/ml and 338 × 106 cells/l, respectively. At week 204, 72 patients remained on study, 70 of whom had HIV-1 RNA < 50 copies/ml (70% by intent-to-treat analysis). Twenty-eight patients discontinued therapy prior to week 204 because of adverse events (n = 10), lost to follow-up (n = 9), or other reasons (n = 9). Of 15 patients who met protocol-defined criteria for virologic failure, seven remained on the study regimen and their HIV-1 RNA was re-suppressed to < 50 copies/ml at week 204. Genotypic analysis of rebound viral isolates was available from 10 patients, including all eight patients who discontinued the study prematurely. No isolate demonstrated primary or active site mutations in protease. The most common adverse events were gastrointestinal symptoms and lipid elevations.

Conclusions: LPV/r-based therapy provides durable antiretroviral response and is generally well tolerated through 204 weeks of therapy.

From the aDuke University Medical Center, Durham, North Carolina, bAbbott Laboratories, Abbott Park, Illinois, cWeill Medical College of Cornell University, New York, dThomas Street Clinic/Baylor College of Medicine, Houston, Texas, eUniversity of North Carolina at Chapel Hill, North Carolina, fDepartments of Medicine and Immunology/Microbiology, Rush Medical College, Chicago, Illinois, gDepartment of Medicine, University of Colorado, Denver, Colorado, hDepartment of Medicine, Northwestern University, Chicago, Illinois, USA.

Requests for reprints to: Dr C. Hicks, Box 3360, Duke University Medical Center, Clinic 2 J South Hospital, Trent Drive, Durham, North Carolina 27710, USA.

Received: 28 April 2003; revised: 14 August 2003; accepted: 29 September 2003.

© 2004 Lippincott Williams & Wilkins, Inc.